FOR PEOPLE WITH HR+/HER2- METASTATIC BREAST CANCER (mBC),

mBC WHAT’S NEXT

Not a real patient.

HER2-= human epidermal growth factor receptor 2-negative; HR+=hormone receptor-positive.

Not a real patient.

HER2-= human epidermal growth factor receptor 2-negative;

HR+=hormone receptor-positive.

Proactive monitoring provides the information you need to catch changes in cancer early, before treatment resistance occurs

A blood test while on your first treatment for metastatic breast cancer may help uncover early signals of cancer changing before they could cause progression (start to grow and spread).

Medical Coverage Icon

GET PROACTIVE MONITORING SUMMARY PDFDownload icon

You and your doctor can use this information to discuss your treatment plan for HR+/HER2- metastatic breast cancer.

 
Doctor Lab Coat Icon

Ask your doctor about repeat testing for ESR1 mutations

 
Dot Pattern Dot Pattern

How can metastatic breast cancer change over time?

Hormone Therapy Pills Icon

How can metastatic breast cancer change over time?

The recommended first treatment for HR+ (hormone receptor-positive)/HER2- (human epidermal growth factor receptor 2-negative) metastatic breast cancer (mBC) includes a type of hormone therapy, called an aromatase inhibitor, and a CDK4/6 inhibitor (cyclin-dependent kinase 4/6 inhibitor).

First hormone therapy

(aromatase inhibitors)

anastrozole exemestane letrozole

 

CDK4/6 inhibitors

abemaciclib palbociclib or ribociclib

Together, these therapies help control
metastatic breast cancer from growing
and spreading.

Over time, metastatic breast cancer can change in response to your first hormone therapy. These changes may cause the treatment to stop working eventually, allowing the cancer to progress (start to grow and spread).

 

Traditionally, a scan showing progression has been required for a doctor to recommend a cancer treatment change. Advancements in testing for ESR1 mutations may show signals that treatment is becoming less effective, detecting them proactively, before progression, so you and your doctor can discuss options proactively.

Aromatase inhibitor:
a type of hormone therapy that treats some breast cancers by blocking estrogen—a hormone that tells cancer to grow. Common types of aromatase inhibitors include anastrozole, letrozole, or exemestane.
CDK4/6 inhibitor:
cyclin-dependent kinase 4/6 inhibitor, a type of cancer treatment that blocks cell division (palbociclib, ribociclib, or abemaciclib).
ESR1 mutation:
estrogen receptor 1 mutation, a change to the ESR1 gene that could cause breast cancer cells to be resistant to some hormone therapies.
HER2- :
human epidermal growth factor receptor 2 negative. Your HER2 status can help determine what treatments may be appropriate for you.
HR+ :
hormone receptor positive. Your HR status can help determine what treatments may be appropriate for you.
Metastatic:
cancer that has spread from the original tumor to other parts of the body.
Progression:
when cancer starts growing or spreading.

Cross PatternDid You Know ESR1 Mutation Badge

Did You Know ESR1 Mutation Badge

One of the early signals of metastatic breast
cancer changing is an ESR1 mutation

Are ESR1 mutations a signal that cancer is changing?

An ESR1 mutation is a change in the cancer's DNA that can develop while on hormone therapy. Having an ESR1 mutation makes it more likely that your first hormone treatment (aromatase inhibitor) for metastatic breast cancer could stop working.

ESR1 mutations are rarely detected at diagnosis. But over time, ~4 out of 10 people with metastatic breast cancer can develop an ESR1 mutation during their first hormone therapy.

Previously, ESR1 mutation testing happened after progression, with a liquid biopsy through a blood test. But, scientists have discovered advancements that allow monitoring before they could cause cancer to progress (start to grow and spread).

 
Waves illustrationWaves illustration

Over time,

~ 4 out of 10 out of 10

people with metastatic breast cancer can develop an ESR1 mutation.

ESR1 Mutation DNA Graphic
Proactive Monitoring Learn More Badge

Why is proactive monitoring in metastatic breast cancer treatment important?

How is proactive monitoring an advancement in catching cancer changes before progression?

Proactive monitoring is an advancement in metastatic breast cancer care. You can speak to your doctor about cancer changes and your treatment plan before progression, helping you stay involved in what may happen next.

Proactive monitoring in action

Proactive Monitoring Test Tube Icon

Proactive monitoring is a part of your regular monitoring routine

 
Blood Test Every 3 Months Calendar Icon

Your doctor will perform a blood test approximately every 3 months to look for ESR1 mutations

 
Repeat Testing Arrows Icon

As part of this routine care, your doctor will repeat testing to determine if any adjustment in your treatment plan may be needed

What else is important to know about proactive monitoring for metastatic breast cancer treatment?

Proactive monitoring consists of a blood test that fits into your regular monitoring routine (approximately every 3 months), making it possible to catch these changes early.

 

These blood tests are also known as ctDNA (circulating tumor DNA) tests, because they look for traces of cancer DNA that is shed into the bloodstream. ctDNA tests may have many uses, including determining if a treatment is working.

Patient Portrayal Woman with Metastatic Breast Cancer

Not a real patient.

Not a real patient.

Talk to your care team about early detection of cancer changes while on your first hormone treatment for metastatic breast cancer

 
 

Your guide to looking ahead for early signals of progression

1/10
 

Short on time?
Take this information with you:

 
ESR1 Testing Lab Coat Icon

Continue learning about testing for ESR1 mutations proactively and looking ahead for signals of metastatic breast cancer progression

 
Stay Connected Envelope Icon

Stay connected

All fields are required: